Top

Published in:

01-03-2022 | Tocilizumab | Review Article

Castleman disease and TAFRO syndrome

Authors: Yasufumi Masaki, Kotaro Arita, Tomoyuki Sakai, Kazue Takai, Sadao Aoki, Hiroshi Kawabata

Published in: Annals of Hematology | Issue 3/2022

Abstract

Although Castleman disease was first described in 1956, this disease includes various conditions, including unicentric Castleman disease with hyaline vascular histology, human herpesvirus-8 (HHV-8) related multicentric Castleman disease, idiopathic multicentric Castleman disease, and mimics of Castleman disease associated with other conditions. To date, Castleman disease remains incompletely understood due to its rareness and difficulties in clinical and pathological diagnosis. TAFRO syndrome was reported in Japan in 2010. Because lymph node histology is similar in patients with TAFRO syndrome and Castleman disease, TAFRO syndrome is described as a related disorder of Castleman disease. Clinically, however, these conditions differ markedly. Although elevated interleukin-6 (IL-6) expression is characteristic of Castleman disease, increased expression of IL-6 may occur in patients with other diseases, making elevated IL-6 unsuitable for differential diagnosis. Further understanding of these disorders requires the identification of novel disease-specific biomarkers. This review article therefore outlines the characteristics of Castleman disease and TAFRO syndrome.

Castleman B, Iverson L, Menendez VP (1956) Localized mediastinal lymph node hyperplasia resembling lymphoma. Cancer 9:822–830. https://doi.org/10.1002/1097-0142(195607/08)9:4%3c822::aid-cncr2820090430%3e3.0.co;2-4CrossRefPubMed

Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129:1646–1657. https://doi.org/10.1182/blood-2016-10-746933CrossRefPubMedPubMedCentral

Kurose N, Futatsuya C, Mizutani KI, Kumagai M, Shioya A, Guo X, Aikawa A, Nakada S, Fujimoto S, Kawabata H, Masaki Y, Takai K, Aoki S, Kojima M, Nakamura S, Yamada S (2018) The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77:130–138. https://doi.org/10.1016/j.humpath.2018.04.001CrossRefPubMed

Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, Zhu XL, Liu XY, Sun KLA (2010) retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients. Med Oncol 27:1171–1178. https://doi.org/10.1007/s12032-009-9355-0CrossRefPubMed

Talat N, Belgaumkar AP, Schulte KM (2012) Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg 255:677–684. https://doi.org/10.1097/SLA.0b013e318249dcdcCrossRefPubMed

Jiang JP, Shen XF, Du JF, Guan WX (2018) A retrospective study of 34 patients with unicentric and multicentric Castleman’s disease: experience from a single institution. Oncol Lett 15:2407–2412. https://doi.org/10.3892/ol.2017.7625CrossRefPubMed

Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH (2017) Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129:1658–1668. https://doi.org/10.1182/blood-2016-11-748855CrossRefPubMedPubMedCentral

Masaki Y, Kawabata H, Fujimoto S, Kawano M, Iwaki N, Kotani T, Nakashima A, Kurose N, Takai K, Suzuki R, Aoki S (2019) Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop 59:175–178. https://doi.org/10.3960/jslrt.19021CrossRefPubMedPubMedCentral

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC (2019) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132:2115–2124. https://doi.org/10.1182/blood-2018-07-862334CrossRef

10.

Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, Kurose N, Ide M, Murakami J, Nara K, Yamamoto H, Ozawa Y, Takahashi H, Miura K, Miyauchi T, Yoshida S, Momoi A, Awano N, Ikushima S, Ohta Y, Furuta N, Fujimoto S, Kawanami H, Sakai T, Kawanami T, Fujita Y, Fukushima T, Nakamura S, Kinoshita T, Aoki S (2016) Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103:686–692. https://doi.org/10.1007/s12185-016-1979-1CrossRefPubMed

11.

Takai K, Nikkuni K, Shibuya H, Hashidate H (2010) Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki 51:320–325 (in Japanese)PubMed

12.

Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, Masunari T, Yoshida I, Moro H, Nikkuni K, Takai K, Matsue K, Kurosawa M, Hagihara M, Saito A, Okamoto M, Yokota K, Hiraiwa S, Nakamura N, Nakao S, Yoshino T, Sato Y (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220–226. https://doi.org/10.1002/ajh.24242CrossRefPubMed

13.

Nishimura Y, Fajgenbaum DC, Pierson SK, Iwaki N, Nishikori A, Kawano M, Nakamura N, Izutsu K, Takeuchi K, Nishimura MF, Maeda Y, Otsuka F, Yoshizaki K, Oksenhendler E, van Rhee F, Sato Y (2021) Validated International Definition of the TAFRO clinical subtype of idiopathic multicentric Castleman disease. Am J Hematol. https://doi.org/10.1002/ajh.26292CrossRefPubMed

14.

Dispenzieri A, Fajgenbaum DC (2020) Overview of Castleman disease. Blood 135:1353–1364. https://doi.org/10.1182/blood.2019000931CrossRefPubMed

15.

Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, Kurose N, Miura K, Nakamura S, Aoki S, Japanese TAFRO Syndrome Research Team (2020) 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111:155–158. https://doi.org/10.1007/s12185-019-02780-1CrossRefPubMed

16.

Kawabata H, Fujimoto S, Sakai T, Yanagisawa H, Kitawaki T, Nara K, Hagihara M, Yamamoto H, Tanimizu M, Kato C, Origuchi T, Sunami K, Sunami Y, Masunari T, Nakamura N, Kobayashi M, Yamagami K, Miura K, Takai K, Aoki S, Tsukamoto N, Masaki Y (2021) Patient’s age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol 114:179–188. https://doi.org/10.1007/s12185-021-03159-xCrossRefPubMed

17.

Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, Ohara S, Tsukamoto N, Kurose N, Yamada S, Takai K, Aoki S, Masaki Y (2021) Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol 113:73–80. https://doi.org/10.1007/s12185-020-03008-3CrossRefPubMed

18.

Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, Aoki S, Kuroda J, Ide M, Setoguchi K, Tsukamoto N, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Masaki Y (2019) Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94:975–983. https://doi.org/10.1002/ajh.25554CrossRefPubMed

19.

Suichi T, Misawa S, Sekiguchi Y, Shibuya K, Tsuneyama A, Suzuki YI, Nakamura K, Kano H, Kuwabara S (2020) Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease. J Neurol Sci 413:116771. https://doi.org/10.1016/j.jns.2020.116771CrossRefPubMed

20.

Sato Y, Notohara K, Kojima M, Takata K, Masaki Y, Yoshino T (2010) IgG4-related disease: historical overview and pathology of hematological disorders. Pathol Int 60:247–258. https://doi.org/10.1111/j.1440-1827.2010.02524.xCrossRefPubMed

21.

Shiroshita K, Kikuchi T, Okayama M, Kasahara H, Kamiya T, Shimizu T, Kurose N, Masaki Y, Okamoto S (2020) Interleukin-6-producing intravascular large B-cell lymphoma with lymphadenopathy mimicking the histology of multicentric Castleman disease. Intern Med 59:3061–3065. https://doi.org/10.2169/internalmedicine.5046-20CrossRefPubMedPubMedCentral

22.

Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Doai M, Matoba M, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Mizumaki Y, Yamaguchi M, Masaki Y (2019) Osteosarcoma manifesting systemic inflammation and histological features mimicking plasma cell type Castleman disease. Intern Med 58:2555–2560. https://doi.org/10.2169/internalmedicine.2738-19CrossRefPubMedPubMedCentral

23.

Fujimoto S, Kawabata H, Kurose N, Kawanami-Iwao H, Sakai T, Kawanami T, Fujita Y, Fukushima T, Masaki Y (2017) Sjögren’s syndrome manifesting as clinicopathological features of TAFRO syndrome: a case report. Medicine 96:e9220. https://doi.org/10.1097/MD.0000000000009220CrossRefPubMedPubMedCentral

Title: Castleman disease and TAFRO syndrome
Authors: Yasufumi Masaki
Kotaro Arita
Tomoyuki Sakai
Kazue Takai
Sadao Aoki
Hiroshi Kawabata
Publication date: 01-03-2022
Publisher: Springer Berlin Heidelberg
Keywords: Tocilizumab
Kaposi's Sarcoma-Associated Herpesvirus
Rituximab
Thrombocytopenia
Cytokines
Lymphadenopathy
Rituximab
Castleman Disease
Published in: Annals of Hematology / Issue 3/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-022-04762-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major

Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area

Liquid biopsies of plasma and cerebrospinal fluid are useful for detection of intravascular lymphoma with central nervous system symptoms alone

Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation

Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials